Research Highlight |
Featured
-
-
Review Article |
Claudin 18.2 as a novel therapeutic target
The development and successful phase III testing of the anti-claudin 18.2 antibody zolbetuximab has provided a novel targeted therapy for the 30–40% of patients with strongly claudin 18.2-positive gastric cancers. Furthermore, the development of an effective targeted therapy for a target that does not have a driver role in cancer development provides a novel drug development paradigm. In this Review, the authors describe the development of claudin 18.2-targeted therapies, including zolbetuximab, as well as novel therapies, including chimeric antigen receptor (CAR) T cells, antibody–drug conjugates and bispecific antibodies, all of which have the potential to expand the number of patients who can derive benefit from claudin 18.2-targeted therapies in the near future.
- Izuma Nakayama
- , Changsong Qi
- & Kohei Shitara
-
Review Article |
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
Globally, gastric cancer is a common and highly fatal cancer with two anatomical subtypes, non-cardia and cardia gastric cancer. Helicobacter pylori causes almost 90% of distal gastric cancers worldwide. The authors of this Review summarize the current epidemiology of gastric cancer and the evidence and implications of primary and secondary prevention efforts.
- Aaron P. Thrift
- , Theresa Nguyen Wenker
- & Hashem B. El-Serag
-
-
-
Perspective |
Rising incidence of early-onset colorectal cancer — a call to action
The incidence of early-onset colorectal cancer (CRC) is increasing worldwide for reasons that are currently unclear. Herein, the authors review the current epidemiological, clinical, pathological and molecular understanding of early-onset CRC that occurs in patients ≥50 years of age, drawing contrasts with later-onset CRC. They also discuss future research strategies for improved understanding, prevention, early detection and clinical management of early-onset CRC.
- Naohiko Akimoto
- , Tomotaka Ugai
- & Shuji Ogino
-
-
-
-
Research Highlight |
Driver genes are mutated early in the course of oesophageal adenocarcinoma
- Natalie J. Wood
-
Review Article |
Management of colorectal cancer presenting with synchronous liver metastases
Around 20% of patients with colorectal cancer (CRC) have synchronous hepatic metastases at the time of presentation, highlighting the need for appropriate diagnostic and staging assessments. Furthermore, various approaches to the therapeutic management of such patients are available, and the treatment strategy used is influenced by clinical presentation. Herein, these aspects of the management of patients with CRC and synchronous liver metastases are comprehensively reviewed, focusing on the integration of surgical approaches within a multidisciplinary framework.
- Ajith K. Siriwardena
- , James M. Mason
- & Santhalingam Jegatheeswaran
-
News & Views |
Adjuvant chemotherapy for rectal cancer—an unresolved issue
Several clinical trials have addressed the role of adjuvant chemotherapy following neoadjuvant chemoradiation and surgery for rectal cancer. The recently published EORTC 22921 study adds further debate to the merits of adjuvant chemotherapy in this setting.
- Manisha Palta
- , Brian G. Czito
- & Christopher G. Willett
-
-
-
Correspondence |
The treatment of severe hepatitis B virus reactivation after chemotherapy
- Xing Li
- , Yan-Fang Xing
- & Xiang-Yuan Wu
-
The PROs and cons of liver resection in colorectal cancerBrowse broader subjects
Browse narrower subjects
- Anal diseases
- Biliary tract disease
- Dysbiosis
- Enteric neuropathies
- Functional gastrointestinal disorders
- Gastroenteritis
- Gastrointestinal bleeding
- Gastrointestinal cancer
- Hepatitis
- Inflammatory bowel disease
- Intestinal diseases
- Liver diseases
- Motility disorders
- Nutrition disorders
- Oesophageal diseases
- Pancreatic disease
- Stomach diseases
- Ulcers
